These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 34859693)

  • 41. Costs and staffing resource requirements for adaptive clinical trials: quantitative and qualitative results from the Costing Adaptive Trials project.
    Wilson N; Biggs K; Bowden S; Brown J; Dimairo M; Flight L; Hall J; Hockaday A; Jaki T; Lowe R; Murphy C; Pallmann P; Pilling MA; Snowdon C; Sydes MR; Villar SS; Weir CJ; Welburn J; Yap C; Maier R; Hancock H; Wason JMS
    BMC Med; 2021 Oct; 19(1):251. PubMed ID: 34696781
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
    Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
    Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Incorporation of sequential trials into a fixed effects meta-analysis.
    Todd S
    Stat Med; 1997 Dec; 16(24):2915-25. PubMed ID: 9483723
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adaptive trial designs.
    Lai TL; Lavori PW; Shih MC
    Annu Rev Pharmacol Toxicol; 2012; 52():101-10. PubMed ID: 21838549
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Practical help for specifying the target difference in sample size calculations for RCTs: the DELTA
    Cook JA; Julious SA; Sones W; Hampson LV; Hewitt C; Berlin JA; Ashby D; Emsley R; Fergusson DA; Walters SJ; Wilson EC; MacLennan G; Stallard N; Rothwell JC; Bland M; Brown L; Ramsay CR; Cook A; Armstrong D; Altman D; Vale LD
    Health Technol Assess; 2019 Oct; 23(60):1-88. PubMed ID: 31661431
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Interventions based on early intensive applied behaviour analysis for autistic children: a systematic review and cost-effectiveness analysis.
    Rodgers M; Marshall D; Simmonds M; Le Couteur A; Biswas M; Wright K; Rai D; Palmer S; Stewart L; Hodgson R
    Health Technol Assess; 2020 Jul; 24(35):1-306. PubMed ID: 32686642
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Choosing Interim Sample Sizes in Group Sequential Designs.
    Tarima S; Flournoy N
    Stud Health Technol Inform; 2021 May; 278():11-16. PubMed ID: 34042870
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Exact critical values for group sequential designs with small sample sizes.
    Rom DM; McTague JA
    J Biopharm Stat; 2020 Jul; 30(4):752-764. PubMed ID: 32151177
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Optimal promising zone designs.
    Hsiao ST; Liu L; Mehta CR
    Biom J; 2019 Sep; 61(5):1175-1186. PubMed ID: 30411405
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adaptive designs at European Organisation for Research and Treatment of Cancer (EORTC) with a focus on adaptive sample size re-estimation based on interim-effect size.
    Mauer M; Collette L; Bogaerts J;
    Eur J Cancer; 2012 Jun; 48(9):1386-91. PubMed ID: 22281098
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Overview, hurdles, and future work in adaptive designs: perspectives from a National Institutes of Health-funded workshop.
    Coffey CS; Levin B; Clark C; Timmerman C; Wittes J; Gilbert P; Harris S
    Clin Trials; 2012 Dec; 9(6):671-80. PubMed ID: 23250942
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A novel Bayesian adaptive design incorporating both primary and secondary endpoints for randomized IIB chemoprevention study of women at increased risk for breast cancer.
    Gajewski BJ; Kimler BF; Koestler DC; Mudaranthakam DP; Young K; Fabian CJ
    Trials; 2022 Dec; 23(1):981. PubMed ID: 36471449
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation by simulation of clinical trial designs for evaluation of treatment during a viral haemorrhagic fever outbreak.
    Manchon P; Belhadi D; Mentré F; Laouénan C
    BMC Med Res Methodol; 2021 May; 21(1):98. PubMed ID: 33952195
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Estimating the Expected Value of Sample Information across Different Sample Sizes Using Moment Matching and Nonlinear Regression.
    Heath A; Manolopoulou I; Baio G
    Med Decis Making; 2019 May; 39(4):346-358. PubMed ID: 31161867
    [No Abstract]   [Full Text] [Related]  

  • 55. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
    Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Assessing methods to specify the target difference for a randomised controlled trial: DELTA (Difference ELicitation in TriAls) review.
    Cook JA; Hislop J; Adewuyi TE; Harrild K; Altman DG; Ramsay CR; Fraser C; Buckley B; Fayers P; Harvey I; Briggs AH; Norrie JD; Fergusson D; Ford I; Vale LD
    Health Technol Assess; 2014 May; 18(28):v-vi, 1-175. PubMed ID: 24806703
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Adaptive trial designs in diagnostic accuracy research.
    Zapf A; Stark M; Gerke O; Ehret C; Benda N; Bossuyt P; Deeks J; Reitsma J; Alonzo T; Friede T
    Stat Med; 2020 Feb; 39(5):591-601. PubMed ID: 31773788
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Modifying the design of ongoing trials without unblinding.
    Gould AL; Shih WJ
    Stat Med; 1998 Jan; 17(1):89-100. PubMed ID: 9463852
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sequential allocation trial design in anesthesia: an introduction to methods, modeling, and clinical applications.
    Görges M; Zhou G; Brant R; Ansermino JM
    Paediatr Anaesth; 2017 Mar; 27(3):240-247. PubMed ID: 28211193
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.
    Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C
    Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.